June 18, 2022
A US Food and Drug Administration (FDA) advisory panel has rejected the atypical antipsychotic pimavanserin (Nuplazid, Acadia Pharmaceuticals) for the treatment of Alzheimer’s disease psychosis (ADP). […]
June 17, 2022
The US Food and Drug Administration (FDA) has approved risankizumab-rzaa (Skyrizi, AbbVie) for a third indication — treatment of moderately to severely active Crohn’s disease in […]
June 14, 2022
The US Food and Drug Administration (FDA) has approved vutrisiran (Amvuttra, Alnylam Pharmaceuticals) for the treatment of polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults, the […]
June 14, 2022
The US Food and Drug Administration (FDA) has cleared the first exoskeleton device for use in the rehabilitation of patients with multiple sclerosis (MS). The FDA […]
June 13, 2022
The US Food and Drug Administration (FDA) today approved baricitinib oral tablets as the first systemic treatment for adult patients with severe alopecia areata. The disorder […]
June 13, 2022
A US Food and Drug Administration advisory committee gave a unanimous thumbs up to two new gene therapies: betibeglogene autotemcel (beti-cel) for the treatment of a […]
June 10, 2022
Dr Adam Friedman Those moles, skin tags, and liver spots should stay on your skin until you see a doctor, according to a new alert from […]
June 8, 2022
The US Food and Drug Administration (FDA) has approved brolucizumab (Beovu) for treatment of diabetic macular edema (DME), but included a warning about retinal vasculitis and […]
June 8, 2022
The US Food and Drug Administration (FDA) has announced a Class I recall for Philips Respironics V60 and V60 Plus ventilators, citing a power failure leading […]